Affordable Access

Publisher Website

Trends in Hospitalizations and Mortality From Asthma in Costa Rica Over a 12- to 15-year Period

Authors
Journal
The Journal of Allergy and Clinical Immunology In Practice
2213-2198
Publisher
Elsevier
Volume
2
Issue
1
Identifiers
DOI: 10.1016/j.jaip.2013.09.010
Keywords
  • Asthma
  • Hospitalizations
  • Mortality
  • Costa Rica

Abstract

Background Little is known about trends in morbidity and/or mortality due to asthma in Latin America. Objective To examine trends in hospitalizations and mortality due to asthma from 1997-2000 to 2011 in Costa Rica. Methods The rates of hospitalization due to asthma were calculated for each sex in 3 age groups from 1997 to 2011. The number of deaths due to asthma was first calculated for all groups and then for each sex in 3 age groups from 2000 to 2011. All analyses were conducted over the entire period and separately for the periods before and after a National Asthma Program (NAP) in 2003. Data also were available for prescriptions for beclomethasone since 2004. All analyses were conducted by using Epi Info. Results Substantial reductions were found in hospitalizations and deaths due to asthma in Costa Ricans (eg, from 25 deaths in 2000 to 5 deaths in 2011). Although, the percentage decrement in the rates of hospitalization for asthma in subjects <20 years old was similar before and after the NAP, the reduction in both deaths due to asthma and rates of asthma hospitalizations in older subjects were more pronounced after the NAP, when prescriptions for beclomethasone were also increased by approximately 129%. Conclusion In Costa Rica, there was a marked decrement in hospitalizations and mortality due to asthma from 1997-2000 to 2011. In younger subjects, this is likely due to guidelines that, since 1988, recommend inhaled corticosteroids for persistent asthma. In older adults, the NAP probably enhanced reductions in hospitalizations and deaths due to asthma through inhaled corticosteroid use.

There are no comments yet on this publication. Be the first to share your thoughts.